帕妥珠单抗联合新辅助化疗对HER-2阳性乳腺癌患者的临床疗效  

Clinical Efficacy of Patuzumab Combined with Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients

作　　者：史磊[1] 曹非 张帅 SHI Lei;CAO Fei;ZHANG Shuai(Department of Oncology,Luohe Central Hospital,Luohe 462000,China)

机构地区：[1]漯河市中心医院肿瘤科,河南漯河462000

出　　处：《河南医学研究》2025年第7期1301-1304,共4页Henan Medical Research

基　　金：河南省科技攻关项目(232102310325)。

摘　　要：目的分析帕妥珠单抗联合TCH新辅助化疗对HER-2阳性乳腺癌的疗效。方法选择2020年8月至2022年8月漯河市中心医院收治的140例HER-2阳性乳腺癌患者,按掷硬币法分为两组,各70例。对照组采取TCH新辅助化疗,观察组采取帕妥珠单抗联合TCH新辅助化疗,比较两组治疗结束时的临床疗效,治疗前、治疗6个疗程转化生长因子-β1(TGF-β1)、血管内皮生长因子(VEGF)指标,统计治疗期间不良反应发生率。结果治疗结束时,观察组总有效率高于对照组(P<0.05);治疗6个疗程后,两组TGF-β1、VEGF水平均低于治疗前,观察组低于对照组(P<0.05);住院期间两组不良反应发生率差异无统计学意义(P>0.05)。结论帕妥珠单抗联合TCH新辅助化疗可有效提高HER-2阳性乳腺癌患者疗效,降低TGF-β1、VEGF水平,减弱肿瘤细胞的转移性和扩散能力,未增加不良反应。Objective To analyze the clinical efficacy of patuzumab combined with TCH neoadjuvant chemotherapy in the treatment of HER-2 positive breast cancer.Methods A total of 140 HER-2 positive breast cancer patients admitted to Luohe Central Hospital from August 2020 to August 2022 were divided into two groups according to the coin toss method,70 cases in each group.The control group was treated with TCH neoadjuvant chemotherapy,while the observation group was treated with a combination of pertuzumab and TCH neoadjuvant chemotherapy.The clinical efficacy of the two groups after treatment and transforming growth factor beta 1(TGF-β1),vascular endothelial growth factor(VEGF)before and after 6 courses of treatment was compared,the incidence of adverse reactions during treatment were calculated.Results After treatment,the total effective rate in the observation group was higher than that in the control group(P<0.05).After 6 courses of treatment,two groups of TGF-β1 and VEGF index was lower than before,and the observation group were lower than control group(P<0.05).During the hospital stay,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Pertuzumab combined with TCH neoadjuvant chemotherapy can effectively improve the clinical efficacy of HER-2 positive breast cancer patients and reduce TGF-β1,VEGF levels,weaken the metastatic and proliferative abilities of tumor cells,without increasing adverse reactions.

关 键 词：乳腺癌 HER-2阳性 新辅助化疗 帕妥珠单抗 疗效 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]